Founder Reflections on 2023

As I reflect on this past year, 2023 finally brought us some wins in reproductive health. And I personally had the opportunity to contribute to landmark steps forward. ⭐️ The FDA made long awaited changes to the mifepristone REMS program to allow pharmacies to dispense the essential medication. I was part of the research team…

Read More

Over-the-Counter Birth Control Pills: FDA Considering HRA Pharma’s Opill

Why Over-the-Counter Birth Control? Oral contraceptives have been around since 1960, and their risks and safety profiles have been well-studied throughout the years. According to the Guttmacher Institute, unplanned pregnancies account for 45% of all pregnancies in the US. Furthermore, nearly one-third of individuals who have tried to obtain a prescription for hormonal contraception report…

Read More

Upcoming Changes to the Mifepristone REMS Program: Implications for Pharmacy Practice

Pharmacists in the community setting may soon have the opportunity to ease access to medication abortion in the United States. In the coming months, mifepristone (Mifeprex) is anticipated to have an updated Risk Evaluation and Mitigation Strategy (REMS) Program that allows dispensing through local brick-and-mortar and mail-order pharmacies. This change will integrate pharmacists into abortion…

Read More

An OTC Birth Control Pill Could Become a Reality

An over-the-counter (OTC) birth control pill is finally on the horizon. HRA Pharma, a French pharmaceutical company, has recently formed a partnership with the nonprofit research organization Ibis Reproductive Health to conduct the research needed to prepare and submit a new drug application for an OTC progestin-only pill to the FDA. While the approval may…

Read More